An interventional study of Micro-punch Excision and Core Excision in Keloid, Keloids and Scars, sponsored by Xijing Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Xijing Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Keloids are fibroproliferative pathological scars characterized by uncontrolled dermal fibroblast proliferation and excessive collagen deposition, typically triggered by skin trauma, recurrent acne, or folliculitis; clinically, they extend beyond the boundaries of the original injury, presenting as elevated, firm, hyperemic papules/nodules and often accompanied by pruritus. As a prevalent condition in dermatology and plastic surgery, keloid pathogenesis and progression are modulated by multifaceted factors (e.g., genetics, tissue tension, anatomical location, immune inflammation), with high-tension sites (e.g., chest, scapulae) associated with poor responses to conservative therapies and elevated recurrence rates.
Per the 2018 Clinical Practice Guidelines for Keloid Management in China, surgery combined with adjuvant radiotherapy is recommended for medium-to-large keloids (2.0-10.0 cm) to mitigate systemic adverse events associated with high-dose local-block therapy. Core excision-currently widely adopted for such lesions-involves resection of the dermal fibrous core while preserving the epidermal/papillary dermal flap to avoid additional incisions; however, it entails substantial trauma, cumbersome operation, and high recurrence when applied to clustered multiple keloids. Micro-punch excision combined with radiotherapy, pioneered by our department, offers minimal invasiveness and tension reduction, yet its efficacy and safety relative to core excision remain uninvestigated (no peer-reviewed literature has directly compared these two approaches for multiple keloids).
The present prospective, self-controlled clinical trial will be conducted in the Department of Dermatology at Xijing Hospital, spanning April 2025 to December 2026. Eligible participants are Han Chinese individuals (18-65 years) with histopathologically confirmed multiple keloids (≥2 lesions in a single anatomical region), meeting: (1) a Japanese Scar Scale (JSS) total score ≥6 or ≥2 individual JSS items (height, hardness, erythema, periscar flush, pain/tenderness, pruritus) scoring ≥2; (2) keloid diameter ≥2 cm, with ineffectiveness after ≥3 cycles of local-block therapy or post-treatment recurrence; (3) planned management with either micro-punch excision + electron beam radiotherapy or core excision + electron beam radiotherapy. Exclusion criteria include anesthesia allergies, systemic comorbidities (e.g., malignancy, immunodeficiency), neurological/psychiatric disorders precluding treatment adherence, pregnancy/lactation, poor follow-up compliance, and concurrent inflammatory skin diseases (e.g., psoriasis).
A total of 20 participants will be enrolled. For each participant, multiple keloids in the target anatomical region will be allocated to two study arms via stratified randomization:
Experimental Arm: Micro-punch excision (0.8-2.4 mm BFY-STE micro-punch, Shandong Shensi Medical Devices Co., Ltd.) under local anesthesia, with 1-mm interval extractions (to visual flatness, deep to the fat layer) followed by open wound pressure dressing; Control Arm: Core excision (incisions parallel to skin tension lines, resection of the fibrous core to the superficial fascia, with marginal scar preservation for tension-free closure) under local anesthesia, followed by subcutaneous 5-0 absorbable suture and pressure dressing.
Adjuvant electron beam radiotherapy (Varian 23EX linear accelerator, 4 MeV energy) will be administered to both arms within 24 hours post-surgery: 16 Gy total dose (4 Gy per session, 4 sessions every other day), with a 1-cm margin around lesions and 0.5-cm shielding film for adjacent normal skin.
Follow-up assessments will be performed at 1, 2, 3, 6, and 12 months post-surgery. Primary endpoints will include the 6-month treatment response rate (defined as ≥30% reduction in Patient and Observer Scar Assessment Scale [POSAS] score vs. baseline) and 6-month POSAS score. Secondary endpoints will encompass the 12-month recurrence rate (defined as POSAS score ≥21), recurrence time, Antaro-3D skin imaging metrics (scar thickness, erythema intensity), JSS score changes, and adverse events (e.g., skin atrophy, pigmentation, vascular dilatation).
Severe adverse events (e.g., wound infection/dehiscence, radiation-induced hematological/hepatic/renal impairment) will trigger immediate study termination; routine monitoring (daily 7-day post-surgery follow-up for pain/temperature, blood routine/hepatic-renal function tests at 3/6 months) will be implemented to capture adverse events.
This study aims to compare the clinical outcomes and safety profiles of micro-punch excision vs. core excision (both combined with electron beam radiotherapy) for multiple keloids. Findings are anticipated to identify an optimal therapeutic strategy for multiple keloids and establish evidence-based support for the standardized application of micro-punch excision in clinical practice.
I. Background Keloids are fibroproliferative pathological scars caused by excessive dermal fibroblast proliferation, triggered by skin trauma, recurrent acne, or folliculitis. Clinically, they extend beyond the original injury, present as elevated, firm hyperemic lesions with pruritus, and are common in dermatology and plastic surgery. Pathologically, they feature fibroblast overproliferation and collagen overproduction, with genetics, tissue tension, location, and lesion count among key modulators of progression and prognosis. High-tension sites (chest, scapulae) respond poorly to conservative therapy and have high recurrence rates; more lesions and younger onset further worsen outcomes.
Per the 2018 *Chinese Clinical Practice Guidelines for Keloid Management*, surgery + radiotherapy is recommended for 2.0-10.0 cm keloids (to avoid systemic risks of high-dose local blocking). Core excision-widely used for such lesions-removes the fibrous core while preserving epidermal/papillary flaps to avoid new incisions, but is traumatic and cumbersome for clustered multiple keloids. Our department pioneered micro-punch excision + radiotherapy, a minimally invasive technique that reduces tension and recurrence, yet its efficacy vs. core excision remains unstudied. No literature compares these approaches for multiple keloids, creating an urgent need for evidence-based research.
This prospective self-controlled trial (April 2025-December 2026, Xijing Hospital Dermatology) will enroll patients with ≥2 keloids (mandible/chest/back/scapulae). Lesions in the same site will be randomized to micro-punch excision + electron beam radiotherapy (experimental) or core excision + electron beam radiotherapy (control). Primary endpoints: 6-month response rate and POSAS scores; secondary endpoints: 1-year recurrence rate. The goal is to validate optimal regimens and establish evidence for standardized micro-punch use.
II. Study Objectives
Primary Objective: Compare efficacy and safety of micro-punch excision vs. core excision for keloids via self-controlled experimental design.
III. Study Design \& Procedures
Study Design
Type: Prospective experimental study; Design: Self-controlled (same-patient lesion randomization).
Enrollment \& Randomization: Recruit 20 Han patients (18-65 years) with ≥2 keloids. After informed consent, randomize lesions via stratified methods: ≤6 lesions (split left/right + random number table); ≥6 uniform lesions (split by anatomical midline + random number table); ≥6 uneven lesions (numbered + random number table).
Baseline \& Post-Treatment Assessments: Collect demographics/lesion photos; assess via POSAS and JSS pre- and post-treatment. For ≤6 lesions: individual assessment; ≥6 lesions: subgroup assessment (by area/quantity).
Follow-Up: 1, 2, 3, 6, 12 months post-surgery. Evaluate 6-month response rate, 12-month recurrence rate/time, scar thickness/erythema (Antaro-3D), and adverse events (AEs).
IV. Patient Selection
Inclusion Criteria
Exclusion Criteria
Withdrawal: Poor follow-up compliance.
Termination: Immediate for severe AEs (infection, wound dehiscence, radiotherapy-induced hematological/hepatic/renal impairment, severe acne). Mild erythema/pigmentation/pain (self-resolving) requires no intervention.
V. Methods \& Technical Route
Treatment Protocols
Efficacy Assessment (Single-Blind)
VI. Outcome Measures \& Follow-Up Timing
Primary Outcomes: 6-month response rate, 6-month POSAS scores.
Secondary Outcomes: 12-month recurrence rate, Antaro-3D scores, JSS changes, recurrence time, AEs (atrophy, vascular dilatation, pigmentation).
Follow-Up: 1, 2, 3, 6, 12 months (in-person/telephone); blood routine/hepatic-renal function tests at 3/6 months.
VII. Adverse Event Monitoring
Monitor AEs (severe infection, wound dehiscence, radiotherapy toxicities). Daily follow-up (7 days post-op) for temperature/pain; free dressing change/topical antibiotics for treatment-related infection.
VIII. Statistical Analysis
SPSS 26.0 software for data analysis; compare efficacy/safety between groups using appropriate statistical methods.
139 studies on the registry are indexed under Keloid; 26 are open to participants now.
This study's enrollment of 90 is above the median of 30 across 110 interventional studies indexed under Keloid.
Browse Keloid studies →Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After local anesthesia, a 0.8-2.4 mm BFY-STE micro-punch (Shandong Shensi Medical Devices Co., Ltd.) is used to extract keloid tissue at high density with 1-mm intervals between drill holes, ensuring even coverage. The drilling depth reaches the fat layer, and radial extraction is performed if necessary to achieve visually flat appearance during the operation. The excised tissue is removed through the side hole by means of negative pressure and the rotational force of the drill bit. After treatment, the wound is left open and covered with pressure dressing.
Procedure: Micro-punch Excision · Radiation: Electron Beam Radiotherapy
Routine disinfection and incision marking are performed first, with incisions designed parallel to skin tension lines. Local anesthesia is administered using 1% lidocaine. The keloid is incised from the edge, and most of the scar tissue is excised down to the superficial fascia layer, while a portion of the marginal scar tissue is preserved to ensure tension-free wound closure and maintain blood supply to the scar tissue to prevent postoperative flap necrosis. Hemostasis is achieved by gauze compression or bipolar electrocoagulation during the operation. Subcutaneous suture is performed with 5-0 absorbable sutures to avoid dead space, followed by pressure dressing after suture.
Procedure: Core Excision · Radiation: Electron Beam Radiotherapy
After local anesthesia, a 0.8-2.4 mm BFY-STE micro-punch (Shandong Shensi Medical Devices Co., Ltd.) is used to extract keloid tissue at high density with 1-mm intervals between drill holes, ensuring even coverage. The drilling depth reaches the fat layer, and radial extraction is performed if necessary to achieve visually flat appearance during the operation. The excised tissue is removed through the side hole by means of negative pressure and the rotational force of the drill bit. After treatment, the wound is left open and covered with pressure dressing.
Routine disinfection and incision marking are performed first, with incisions designed parallel to skin tension lines. Local anesthesia is administered using 1% lidocaine. The keloid is incised from the edge, and most of the scar tissue is excised down to the superficial fascia layer, while a portion of the marginal scar tissue is preserved to ensure tension-free wound closure and maintain blood supply to the scar tissue to prevent postoperative flap necrosis. Hemostasis is achieved by gauze compression or bipolar electrocoagulation during the operation. Subcutaneous suture is performed with 5-0 absorbable sutures to avoid dead space, followed by pressure dressing after suture.
Radiotherapy is administered within 24 hours after surgery, using a Varian 23EX linear accelerator (4 MeV energy, USA). The irradiation range extends 1 cm beyond the scar tissue, with a total radiation dose of 16 Gy, administered 4 times every other day (4 Gy per session). A 0.5 cm radiotherapy shielding film is applied around the wound during irradiation to protect the normal skin tissue surrounding the lesion.
6-month response rate
The clinical efficacy evaluation criteria were as follows: ① Cure: keloids were completely softened and flattened, with no pain and itch, and no recurrence was observed during a 1-year follow-up after treatment. ② Significant Efficacy: 60-70% of keloids became softer and flatter, with pain and itch disappeared or significantly alleviated, and no aggravation was observed during a 1-year follow-up after treatment. ③ Effective: 10-59% of keloids was improved compared with pretreatment, with pain and itch relieved. ④ Ineffective:≤10% of keloids improved or no change after treatment, without pain and itch relieved. ⑤ Recurrence: palpable nodules or plaque were observed, or the elevation and induration of keloids were severer compared with pretreatment during evaluation . The effective rate was calculated as \[(number of cured cases + number of significantly effective cases + number of effective cases)/total number of cases\] × 100%
Time frame: From enrollment to the end of treatment at 6 months
POSAS scores
The Patient and Observer Scar Assessment Scale (POSAS) is a validated, dual-perspective tool widely employed in dermatology and plastic surgery for comprehensive scar evaluation, integrating both subjective patient experiences and objective clinical observations.The Patient Scale (POSAS 3.0, generic version) consists of 16 items, rated by patients on a 5-point Likert scale by comparing scars to surrounding normal skin. It assesses scar appearance , sensory feelings and psychosocial impacts . Two satisfaction items use reverse scoring, with the total score ranging from 16 to 80-higher scores indicate poorer scar outcomes. A 17th item is added for linear scars.The Observer Scale is completed by trained clinicians, using a 10-point scale against normal skin at a comparable anatomical site. It includes 6 objective metrics plus an independent Overall Opinion score (1-10). The total score for the first 6 items is 6-60, with higher scores reflecting more severe scarring.
Time frame: From enrollment to the end of treatment at 6 months
12-month recurrence rate
The clinical efficacy evaluation criteria were as follows: ① Cure: keloids were completely softened and flattened, with no pain and itch, and no recurrence was observed during a 1-year follow-up after treatment. ② Significant Efficacy: 60-70% of keloids became softer and flatter, with pain and itch disappeared or significantly alleviated, and no aggravation was observed during a 1-year follow-up after treatment. ③ Effective: 10-59% of keloids was improved compared with pretreatment, with pain and itch relieved. ④ Ineffective:≤10% of keloids improved or no change after treatment, without pain and itch relieved. ⑤ Recurrence: palpable nodules or plaque were observed, or the elevation and induration of keloids were severer compared with pretreatment during evaluation
Time frame: From enrollment to the end of treatment at 12 months
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Oct 2026, 18 months.
Of 21 interventional studies with no phase under Keloid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's 18 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.